We're developing first-in-class inhalable and infection-activated RNA therapeutics from COVID-19 and influenza to RSV. Our lead candidate provides single-administration protection against any coronavirus.
USSF located in Allentown, Pennsylvania, Dr. Flanigan is leading his team to bring QYNDR, an oral mucosal vaccine delivery platform currently targeting the COVID-19 vaccine, to market – one that will be easier to use, longer lasting and with fewer...